Phase III (Krascendo 1) demonstrates best-in-class potential for patients with previously treated advanced KRAS G12C non-small cell lung cancer Diva...
Neurocrine Biosciences, Inc. announced the initiation of its Phase 2 clinical study to assess the safety and tolerability of crinecerfont in ...
Corten Capital and Ampersand Capital Partners (“Ampersand”) are pleased to announce the completion of their acquisition of Beacon Intelligenc...
AXELIOS 1 delivers a unique combination of accuracy, speed, scalability and cost efficiency, giving laboratories of all sizes the freedom to customise ...
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, tod...
Scientists can now search, understand and act on complex R&D data in natural language by leveraging leading LLM capabilities within the Signals O...
Contamination control is no longer viewed solely through the lens of compliance. Across today's biopharmaceutical manufacturing landscape, it has become a ...
The Novo Nordisk Foundation is funding a new pan-European initiative to accelerate drug discovery and the development of next generation therapeutics for...
Clinical Trial approval for TCX-001 is another significant development milestone for T-CURX and marks the transition of T-CURX from a pre-clinical to a...
EBGLYSS is now the only approved option that offers as few as six maintenance injections per year with no required topicals from the ...
The partnership combines Sapio Platform capabilities with ZS consulting expertise to deliver integrated laboratory solutions Sapio Sciences, the AI lab i...
Service will be available to clinicians and healthcare providers to support patient assessments and diagnosis Scottish Brain Sciences (SBS) has ...
Phase I study of an AI-designed oral formulation sets a new standard in drug development Quotient Sciences announces the successful initiation of a...
Award funds collaboration with leading Parkinson’s researcher, Dr. Tim Greenamyre, to investigate a novel therapeutic approach for Parkinson&rsqu...
© 2026 Biopharma Boardroom. All Rights Reserved.
